KEYNOTE-789: Chemotherapy With or Without Pembrolizumab for TKI-Resistant Nonsquamous NSCLC

In the phase 3 CheckMate-77T trial, a neoadjuvant and adjuvant treatment strategy including nivolumab and chemotherapy improved survival in resectable stage IIA to IIIB non–small cell lung cancer.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed which patients with non–small cell lung cancer should receive immunotherapy-containing regimens. This is the second of 2 articles based on this event.

Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.

Atezolizumab, carboplatin, and pemetrexed demonstrated efficacy and safety in patients with advanced lung cancer with untreated brain metastases.

According to research led by Tetsuya Mitsudomi, MD, perioperative durvalumab plus chemotherapy may be better than placebo plus chemotherapy for the treatment of resectable non–small cell lung cancer.